ARAIArrive AI Inc.
Arrive AI Inc. (ARAI) sells AI-driven logistics and delivery solutions for the pharmaceutical and healthcare sectors. Its next catalyst is Nov 13, 2026 — Q3 2026 Earnings Release, which will test whether the company can deliver improved unit economics and a path to positive cash flow. The stock has struggled to clear the $0.35 bear floor, with recent weakness tied to unmet expectations around its pharmacy partnership and lack of concrete financial traction .
- Revenue in 2026 is $127,800, but net income is -$29.05M, with a TTM net margin of -22,733.5%.
- Free cash flow is -$18.75M over the last 12 months, and shareholders’ equity is $2.48M.
- The company is heavily leveraged, with a negative equity position and no clear path to profitability.
The Read
Arrive AI's stock fell 34%.6% after its NACUFS showcase failed to generate momentum, then declined further as in-line Q2 earnings and a preliminary pharmacy partnership lacked concrete financial impact, keeping shares below the $0.35 bear floor.
The schedule
- Sun1Nov
Management is likely to pursue and highlight at least one notable AI infrastructure or logistics partnership by late 2026; from a depressed $0.25 base, a credible customer deployment could lift Arrive AI Inc. toward $0.60, while a lack of traction or underwhelming terms could leave shares hovering closer to $0.2.
- Fri13Nov
The earnings release will test whether the company can deliver a positive guidance reset, particularly on margin and cash burn, which historically have been key drivers of price movement for similar names.
- Fri12Feb
This release will test the company's ability to show progress in scaling its AI logistics platform, with a focus on customer acquisition and retention metrics, which are critical for this issuer's valuation.
- Wed31Mar
The Nasdaq listing review will test the company's ability to meet compliance requirements, which could lead to a reverse split and impact liquidity.
- Fri14May
The earnings release will test the company's ability to show a clear path to profitability, particularly through improved unit economics and scaling of its AI-driven logistics solutions.
- Thu12Aug
Past
- Mon12Oct
Actual outcome: Bear · $2.02 at outcome
ARAI's stock fell sharply following a regulatory decision that impacted its core product's approval timeline. The move suggests a negative outcome, such as a delayed or denied regulatory clearance, which would affect its commercialization plans and revenue outlook. The event likely occurred just before the price window, triggering a rapid sell-off. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-11-12: -27.1% from 2026-11-11 (~3.2σ). Target date 2026-10-22 reached; move through 2026-11-12 observed.
ARAI's stock fell sharply following a regulatory decision that impacted its core product's approval timeline. The move suggests a negative outcome, such as a delayed or denied regulatory clearance, which would affect its commercialization plans and revenue outlook. The event likely occurred just before the price window, triggering a rapid sell-off. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-11-12: -27.1% from 2026-11-11 (~3.2σ). Target date 2026-10-22 reached; move through 2026-11-12 observed.
- Thu13Aug
Actual outcome: Bear
Arrive AI reported Q2 2026 EPS of -$0.11, meeting estimates, and highlighted a growing commercial pipeline alongside the appointment of a new CFO. Although the stock experienced a modest 5.6% bounce following the earnings release, shares closed at $0.25, remaining significantly below the $0.93 bear floor as the results failed to meaningfully reverse the broader negative sentiment.
- Tue4Aug
Actual outcome: Bear · $0.27 at outcome
Arrive AI reported in-line second-quarter results with an EPS of -$0.11, exactly matching analyst estimates, alongside the appointment of a new CFO and a growing commercial pipeline. The company also recently signed a preliminary Letter of Intent with LifeSpan Pharmacy to explore autonomous drone deliveries in Indianapolis. The stock declined as the lack of an earnings beat and the early, exploratory nature of its pharmacy partnership failed to provide the concrete financial catalysts investors were seeking.
- Wed15Jul
Actual outcome: Bear · $0.23 at outcome
Arrive AI showcased its autonomous delivery infrastructure at the NACUFS National Conference, but this operational update failed to generate positive momentum. Instead, the stock fell 34.6% and breached the $0.35 bear floor as ongoing concerns over the company's limited cash position and the looming threat of dilutive equity financing continued to weigh heavily on shares.
With limited cash and rising debt, Arrive AI Inc. is likely to pursue an equity raise or activate an at-the-market program around mid-2026, which could reset the stock from a $0.55 base toward either a stronger, de-risked footing near $0.8 or deeper dilution-driven pressure toward $0.80.
